Company performance
Current Price
as of Dec 10, 2024$90.43
P/E Ratio
N/A
Market Cap
$11.27B
Description
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.
Metrics
Overview
- HQSan Carlos, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerPCVX
- Price$90.43-1.77%
Trading Information
- Market cap$11.27B
- Float96.53%
- Average Daily Volume (1m)1,611,958
- Average Daily Volume (3m)1,061,373
- EPS-$4.68
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$103.12M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$135.42M
- EV$11.98B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B3.29
Documents
SEC Filings
Factset Street Account